Citations

Mayo Clinic

Showing 10 of 108599 citations.

Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: A predominantly population-based study
Asgari, Nasrin , Jarius, Sven , Laustrup, Helle , Skejoe, H.P.B., Lillevang, Søren Thue , Weinshenker, Brian G. , Voss, Anne , Weinshenker, Brian G

Multiple Sclerosis Journal | March 22, 2017 | Volume: 24 | Issue: 3 | Pages: 331-339

10.1177/1352458517699791 | PMID 28326889 Get It

Background: Serum immunoglobulin G targeting the astrocyte water channel aquaporin-4 (AQP4) in the central nervous system (CNS) is a biomarker for neuromyelitis optica spectrum disease (NMOSD). Co-existence of NMOSD with systemic lupus erythematosus (SLE) putatively suggests susceptibility to antibody-mediated autoimmune disease. Objective: To estimate the prevalence of NMOSD in SLE and investigate the immunogenetic background for an association of NMOSD and SLE. Methods: The study included a predominantly population-based cohort with clinical and serological investigations of 208 patients with SLE, followed prospectively since 1995. All patients received immunosuppressive treatment. NMOSD was evaluated retrospectively based on the 2015 International Panel for NMOSD Diagnosis (IPND) criteria. Polymorphisms in programmed cell death protein 1 (PDCD-1) PD-1.3 G/A were genotyped. AGP4-IgG and other autoantibodies, including myelin oligodendrocyte glycoprotein (MOG), was determined blinded to clinical diagnosis. Results: Of 208 patients with SLE, 45(22%) had neuropsychiatric (NP) SLE, and CNS involvement predominated in 30 of 45 (67%) patients. Serum AQP4-IgG was detected in 2 of 30 (6.7%) neuropsychiatric SLE (NPSLE) patients both of whom had myelitis and antiphospholipid syndrome; one patient also had myasthenia gravis. None had MOG-IgG. PD-1.3A allele was not associated with SLE nor with NPSLE. Conclusion: AQP4-IgG autoimmune syndrome may rarely co-exist with SLE, and such patients have other NMOSD-typical syndromes such as myelitis.
Multigenerational pedigree with STAR syndrome: A novel FAM58A variant and expansion of the phenotype
Boczek, Nicole J. , Kruisselbrink, Teresa , Cousin, Margot A. , Blackburn, Patrick R. , Klee, Eric W. , Gavrilova, Ralitza H. , Lanpher, Brendan C.

American Journal of Medical Genetics Part A | March 22, 2017 | Volume: 173 | Issue: 5 | Pages: 1328-1333

10.1002/ajmg.a.38113 | PMID 28322501 Get It

STAR syndrome is a rare X‐linked dominant disorder characterized by toe Syndactyly, Telecanthus, Anogenital malformations, and Renal malformations, and is caused by loss‐of‐function variants in FAM58A. Our proband presented with the hallmark features of STAR syndrome, as well as some additional less typical features including tethered cord and hearing loss. The proband's mother and maternal half‐sister had similar clinical histories, but had variability in phenotypic severity. Clinical whole exome sequencing revealed a novel pathogenic nonsense variant, c.651G>A (p.Trp217X; NM_152274), in FAM58A in the proband, mother, and maternal half‐sister. This pedigree represents the 11–13th patients described with STAR syndrome and the third instance of familial inheritance. To our knowledge, this is the first occurrence of a nonsense variant in FAM58A described in individuals with STAR syndrome and the phenotype in this pedigree suggests that tethered cord and hearing loss are features of STAR syndrome.
Survival benefit needed to undergo chemotherapy: Patient and physician preferences
Vaz-Luís, Inês , O’Neill, Anne, Sepucha, Karen , Baker, Emily, Dang, Chau T. , Northfelt, Donald W. , Schneider, Bryan P. , Miller, Kathy D. , Winer, Eric P. , Sledge, George W. , Partridge, Ann H.

Cancer | March 22, 2017 | Volume: 123 | Issue: 15 | Pages: 2821-2828

10.1002/cncr.30671 | PMID 28323331 Get It

BACKGROUNDPublished studies have suggested that most patients with early stage breast cancer are willing, for modest survival benefits, to receive 6 months of adjuvant cyclophosphamide, methotrexate, and 5‐fluorouracil, an older regimen that is used infrequently today. We examined preferences regarding the survival benefit needed to justify 6 months of a contemporary chemotherapy regimen.METHODSThe Eastern Cooperative Oncology Group Protocol 5103 was a phase 3 trial that randomized breast cancer patients to receive standard adjuvant doxorubicin, cyclophosphamide, and paclitaxel with either bevacizumab or placebo. Serial surveys to assess quality of life were administered to patients enrolled between January 1, 2010, and June 8, 2010. Survival benefit needed to justify 6 months of chemotherapy by patients was collected at the 18‐month assessment. A parallel survey was sent to physicians who had enrolled patients in the study.RESULTSOf 519 patients who had not withdrawn at a time point earlier than 18 months, 87.8% responded to this survey. A total of 175 physicians participated. We found considerable variation in patient preferences, particularly for modest survival benefits: for 2 months of benefit, 57% would consider 6 months of chemotherapy, whereas 96% of patients would consider 6 months of chemotherapy for 24 months. Race and education were associated with the choices. Physicians who responded were less likely to accept chemotherapy for modest benefit.CONCLUSIONSAmong patients who received contemporary adjuvant chemotherapy in a randomized controlled trial, we found substantial variation in preferences regarding benefits that justified undergoing chemotherapy. Differences between patients' and physicians' choices were also apparent. Eliciting preferences regarding risks and benefits of adjuvant chemotherapy is critical. Cancer 2017;123:2821–28. © 2017 American Cancer Society.
Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy
Gopal, Ajay K. , Flowers, Christopher R. , Martin, Peter , Ansell, Stephen M. , Abella-Dominicis, Esteban, Koh, Brian D. , Ye, Wei , Salles, Gilles , Friedberg, Jonathan W. , Kahl, Brad S. , Barr, Paul M. , Salles, Gilles A , Gopal, Ajay

Blood | March 22, 2017 | Volume: 129 | Issue: 22 | Pages: 3037-3039

10.1182/blood-2016-12-757740 | PMID 28325864 Get It

Lower kidney allograft survival in African–Americans compared to Hispanic–Americans with lupus
Contreras, Gabriel, Suarez, Maria Lourdes Gonzalez

Lupus | March 22, 2017 | Volume: 26 | Issue: 12 | Pages: 1269-1277

10.1177/0961203317699287 | PMID 28420070 Get It

Background and objective African–Americans and Hispanic–Americans with lupus are the two most common minority groups who receive kidney transplants in the USA. It is unknown if African–Americans and Hispanic–Americans with lupus have similar outcomes after kidney transplantation. In this study, we assessed whether African–Americans compared to Hispanic–Americans have worse kidney allograft survival after risk factors of rejection and other prognostic factors were matched between both groups. Methods Out of 1816 African–Americans and 901 Hispanic–Americans with lupus, who received kidney transplants between 1987 and 2006 and had complete records in the UNOS program, 478 pairs were matched in 16 baseline predictors and follow-up time employing a predicted probability of group membership. The primary outcome was kidney allograft survival. Main secondary outcomes were rejection, allograft failure attributed to rejection, and mortality. Results Matched pairs were predominantly women (81%) with the mean age of 36 years. 96% were on dialysis before transplantation. 89% of recipients received kidneys from deceased donors and 15.5% from expanded criteria donors. 12% of recipients had zero HLA mismatch. African–Americans compared to Hispanic–Americans had lower cumulative allograft survival during 12-year follow-up ( p < 0.001). African–Americans compared to Hispanic–Americans had higher rates of rejection (10.4 vs 6.73 events/100 patients-years; p = 0.0002) and allograft failure attributed to rejection (6.31 vs 3.99; p = 0.0023). However, African–Americans and Hispanic–Americans had similar mortality rates (2.71 vs 2.31; p = 0.4269). Conclusions African–Americans compared to Hispanic–Americans with lupus had lower kidney allograft survival when recognized risk factors of rejection were matched between groups.
Sessile Serrated Polyps and Colon Cancer Prevention
Rashtak, Shahrooz , Rego, Rafaela L. , Sweetser, Seth , Rego, Rafaela, Sweetser, Seth R, Sinicrope, Frank A.

Cancer Prevention Research | March 22, 2017 | Volume: 10 | Issue: 5 | Pages: 270-278

10.1158/1940-6207.capr-16-0264 | PMID 28325827 Get It

Abstract Evidence suggests that up to one fifth of colorectal carcinomas develop from serrated polyps, named for their pattern of colonic crypts, and include the sessile serrated adenoma/polyp (SSA/P) that has malignant potential. SSA/Ps are typically located in the proximal colon and have molecular features of hypermethylation of CpG islands in gene promoters and activating point mutations (V600E) in the BRAF oncogene. Both of these features are seen in sporadic colorectal carcinomas with microsatellite instability (MSI) which is potentially consistent with an origin of these cancers from precursor SSA/Ps. Dysplasia is detected in a subset of SSA/Ps with a high risk of progression to carcinoma. An uncommon serrated polyp is the traditional serrated adenoma that is typically found in the left colon, has a tubulovillous architecture, and frequently harbors mutant KRAS. To date, the epidemiology of these serrated lesions is poorly understood, and limited observational data suggest a potential chemopreventive benefit of nonsteroidal anti-inflammatory drugs. The current primary strategy to reduce the risk of colorectal carcinoma from serrated polyps is to enhance their detection at colonoscopy and to ensure their complete removal. This review provides insight into the epidemiologic, clinical, histopathologic, and molecular features of serrated polyps and includes data on their endoscopic detection and chemoprevention. Cancer Prev Res; 10(5); 270–8. ©2017 AACR.
Total Analytic Error for Low Cardiac Troponin Concentrations (≤10 ng/L) by Use of a High-Sensitivity Cardiac Troponin Assay
Kavsak, Peter A. , Jaffe, Allan S. , Greene, Dina N. , Christenson, Robert H. , Apple, Fred S. , Wu, Alan H.B. , Jaffe, Allan S. , Greene, Dina , Kavsak, Peter

Clinical Chemistry | March 21, 2017 | Volume: 63 | Issue: 5 | Pages: 1043-1045

10.1373/clinchem.2017.271361 | PMID 28325814 Get It

Surgical Approaches to the Temporal Horn: An Anatomic Analysis of White Matter Tract Interruption
Kadri, Paulo A. S. , Oliveira, Jean Gonçalves de , Krayenbühl, Niklaus , Türe, Uğur , Oliveira, Evandro P. L. de, Al‐Mefty, Ossama , Ribas, Guilherme Carvalhal, de Oliveira, Evandro P L

Operative Neurosurgery | March 21, 2017 | Volume: 13 | Issue: 2 | Pages: 258-270

10.1093/ons/opw011 | PMID 28927207 Get It

Abstract BACKGROUND: Surgical access to the temporal horn is necessary to treat tumors and vascular lesions, but is used mainly in patients with mediobasal temporal epilepsy. The surgical approaches to this cavity fall into 3 primary categories: lateral, inferior, and transsylvian. The current neurosurgical literature has underestimated the interruption of involved fiber bundles and the correlated clinical manifestations. OBJECTIVE: To delineate the interruption of fiber bundles during the different approaches to the temporal horn. METHODS: We simulated the lateral (trans-middle temporal gyrus), inferior (transparahippocampal gyrus), and transsylvian approaches in 20 previously frozen, formalin-fixed human brains (40 hemispheres). Fiber dissection was then done along the lateral and inferior aspects under the operating microscope. Each stage of dissection and its respective fiber tract interruption were defined. RESULTS: The lateral (trans-middle temporal gyrus) approach interrupted “U” fibers, the superior longitudinal fasciculus (inferior arm), occipitofrontal fasciculus (ventral segment), uncinate fasciculus (dorsolateral segment), anterior commissure (posterior segment), temporopontine, inferior thalamic peduncle (posterior fibers), posterior thalamic peduncle (anterior portion), and tapetum fibers. The inferior (transparahippocampal gyrus) approach interrupted “U” fibers, the cingulum (inferior arm), and fimbria, and transected the hippocampal formation. The transsylvian approach interrupted “U” fibers (anterobasal region of the extreme capsule), the uncinate fasciculus (ventromedial segment), and anterior commissure (anterior segment), and transected the anterosuperior aspect of the amygdala. CONCLUSION : White matter dissection improves our knowledge of the complex anatomy surrounding the temporal horn. Identifying the fiber bundles at risk during each surgical approach adds important information for choosing the appropriate surgical strategy.
Psychosocial distress in lymphoma survivors at 3 years’ follow-up.
Allmer, Cristine, Ansell, Stephen M. , Yost, Kathleen J. , Thompson, Carrie A. , Rosenthal, Allison , Maurer, Matthew J. , Farooq, Umar , Habermann, Thomas M. , Link, Brian K. , Witzig, Thomas E. , Cerhan, James R.

Journal of Clinical Oncology | March 21, 2017 | Volume: 35 | Issue: 5_suppl | Pages: 193-193

10.1200/jco.2017.35.5_suppl.193 Get It

193 Background: National standards recommend distress screening as part of cancer care. While many patients report improved quality of life after cancer treatment concludes there remains a population who experience ongoing anxiety and depressive symptoms. We sought to describe psychosocial distress in lymphoma survivors and frequency of visits to mental health providers (MHP). Methods: Lymphoma patients were prospectively enrolled within 9 months of diagnosis in the University of Iowa/Mayo Clinic SPORE Molecular Epidemiology Resource and systematically followed. Brief Profile of Mood States (POMS) and State Trait Anxiety Inventory (STAI) were administered 3 yrs after diagnosis. Lower scores on POMS indicated more distress. A higher score on STAI indicated more anxiety, and a score ≥ 40 was considered clinically significant. Pts were asked if they ever saw a MHP due to their lymphoma. Results: Between 2002-2012, 2465 lymphoma pts age 18-91 (10% 18-40, 54% 41-65, and 36% > 65) were enrolled, met survivor definition, and completed 3-yr POMS and STAI questionnaires. 57% were male. 40% had aggressive and 60% had indolent lymphoma. The median score on STAI 1 (state) was 32 (range 20-76) and on STAI 2 (trait) was 31 (range 20-77). Median POMS total mood disturbance (TMD) score was 88 (range 1-100). 8% of pts reported seeing a MHP. 609 pts (25%) had clinically significant anxiety by STAI 1, 73 (12%) of whom saw a MHP. Those who reported clinically significant anxiety on STAI were more likely to be younger, unemployed, unmarried, and less likely to have seen a MHP. Anxiety levels were similar between those with aggressive lymphoma and indolent lymphoma regardless of treatment. Higher distress levels, measured by TMD, were more often reported by those who were unemployed or over age 65 while there was no association with lymphoma subtype, marital status, or choice of therapy. Conclusions: Clinically significant anxiety was reported in 25% of 3-yr survivors of lymphoma and was associated with younger age, unmarried status, and unemployment. Higher distress levels were associated with older age, and unemployment. However, only 8% of our cohort was seen by a MHP. Identifying distress and appropriately referring to a MHP is important for the optimal care of lymphoma survivors.
Utilization of patient pager for preservation of privacy in clinic waiting room.
Kaleem, Tasneem , Miller, Daniel , Yanez, Maresciel, Buskirk, Steven J.

Journal of Clinical Oncology | March 21, 2017 | Volume: 35 | Issue: 5_suppl | Pages: 192-192

10.1200/jco.2017.35.5_suppl.192 Get It

192 Background: Patient privacy is of the utmost importance for the emotional needs of a cancer patient and their family. As an effort to improve privacy, quality, and coordination of care within our Radiation Oncology department, in 2016 a patient pager system was devised to inform patients to prepare for daily treatment rather than verbally call the patient's name in waiting rooms. Methods: During June 2016, patients undergoing daily radiation therapy participated in a six-question survey addressing various aspects of the paging service, privacy prior to pager use, and demographics. Six radiation therapists also participated in a 7-question survey addressing privacy and workflow. Participants rated their experience on a scale of 1 to 5 (1 being poor, 5 being excellent). Surveys were collected and retrospectively reviewed. Results: 42 patients completed the survey. Patients rated "Very Good" to "Excellent" for the following categories: “Paging system more convenient than being called”(4.6), “Protection of privacy”(4.6), “Easiness”(4.7) and whether “Pager should be utilized for all appointments” (4.3). Patients rated “Patient privacy when name is called” as "Good" to "Very Good" (3.7). Seven patients also underwent therapy prior to pager implementation and rated the new system in comparison as "Very Good" to "Excellent" for “Privacy protection”(4.6), “Efficiency” (4.6), and “Satisfaction” (4.6). Only 24 filled out demographic information. Of the 24 patients, 54% of patients were female, 87% were above the age of 50, and all patients were receiving at least 10 treatments. Staff rated "Fair" to "Very Good" for “More preparation time” (2.8), “Patient use difficulty”(3.2), “Patient positive feedback”(2.3), “Receiving patients” (2.2) and “Workflow” (2). However, “Patient privacy” was rated as "Very Good" to "Excellent" (4.2). Conclusions: Overall, patients and staff highly rated the paging system for protecting privacy in the waiting room. Patients who experienced waiting room procedure prior to pager implementation display greater satisfaction with a paging system. However, it did not change overall workflow. Our study shows clinics should prioritize patient privacy in the waiting room to improve the emotional needs of the patient.